Literature DB >> 18264727

Galectin-9 expression links to malignant potential of cervical squamous cell carcinoma.

Meiyan Liang1, Masaki Ueno, Souichi Oomizu, Tomohiro Arikawa, Rika Shinonaga, Shulan Zhang, Akira Yamauchi, Mitsuomi Hirashima.   

Abstract

PURPOSE: Galectin-9 (Gal-9) induces adhesion and aggregation of certain cell types and can be a prognostic factor in the patients with melanoma and breast cancer. We assessed the experiments to resolve whether Gal-9 expression in cervical neoplasm links to malignant potential of cervical squamous cell carcinoma (SCC) cells.
METHODS: Gal-9 expression was examined with immunohistochemical techniques in 23 normal cervical squamous epithelia, 17 cervical intraepithelial neoplasia (CIN), and 38 cervical SCC compared to E-cadherin. CIN was divided into low-grade and high-grade squamous intraepithelial lesions (8 LSIL and 9 HSIL), and SCC was into well-, moderately and poorly differentiated SCC (6 WSCC, 20 MSCC and 12 PSCC).
RESULTS: Gal-9 and E-cadherin were evidently detected in normal epithelium and endocervical glands, but those in CIN and SCC were significantly faint. Moreover, both the Gal-9 and E-cadherin expressions in HSIL were significant lower than those in LSIL, suggesting their association with malignant transformation. Unexpectedly, Gal-9 and E-cadherin in WSCC were significantly high compared to those in HSIL. Furthermore, those in SCC were inversely correlated with the grade of differentiation (WSCC >> MSCC >> PSCC), implying the possible involvement of Gal-9 and E-cadherin in the differentiation of SCC. In contrast, they were not different among the FIGO stage. Gal-9 expression was well correlated with E-cadherin expression in CIN and SCC but not in normal cervical epithelia.
CONCLUSION: The present results suggest that decreased Gal-9 expression is inversely associated with malignant potential or differentiation of cervical CIN and SCC as a differentiation biomarker.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18264727     DOI: 10.1007/s00432-008-0352-z

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  31 in total

1.  FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics.

Authors:  S Pecorelli; J L Benedet; W T Creasman; J H Shepherd
Journal:  Int J Gynaecol Obstet       Date:  1999-06       Impact factor: 3.561

Review 2.  Introduction to galectins.

Authors:  Hakon Leffler; Susanne Carlsson; Maria Hedlund; Yuning Qian; Francoise Poirier
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

3.  Decreased galectin-3 expression during the progression of cervical neoplasia.

Authors:  Jeong-Won Lee; Sang Yong Song; Jung-Joo Choi; Chel Hun Choi; Tae-Joong Kim; Jhingook Kim; Je-Ho Lee; Byoung-Gie Kim; Duk-Soo Bae
Journal:  J Cancer Res Clin Oncol       Date:  2005-12-21       Impact factor: 4.553

4.  Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin.

Authors:  Pratima Nangia-Makker; Victor Hogan; Yuichiro Honjo; Sara Baccarini; Larry Tait; Robert Bresalier; Avraham Raz
Journal:  J Natl Cancer Inst       Date:  2002-12-18       Impact factor: 13.506

5.  E-cadherin and alpha-catenin expression during tumor progression of cervical carcinoma.

Authors:  E Carico; M Atlante; B Bucci; I Nofroni; A Vecchione
Journal:  Gynecol Oncol       Date:  2001-02       Impact factor: 5.482

6.  Requirement of divalent galactoside-binding activity of ecalectin/galectin-9 for eosinophil chemoattraction.

Authors:  N Matsushita; N Nishi; M Seki; R Matsumoto; I Kuwabara; F T Liu; Y Hata; T Nakamura; M Hirashima
Journal:  J Biol Chem       Date:  2000-03-24       Impact factor: 5.157

7.  A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion.

Authors:  Martyn Plummer; Mark Schiffman; Philip E Castle; Delphine Maucort-Boulch; Cosette M Wheeler
Journal:  J Infect Dis       Date:  2007-04-16       Impact factor: 5.226

8.  Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance.

Authors:  Toshiro Kageshita; Yumiko Kashio; Akira Yamauchi; Masako Seki; Mohammad Jainul Abedin; Nozomu Nishi; Hiroki Shoji; Takanori Nakamura; Tomomichi Ono; Mitsuomi Hirashima
Journal:  Int J Cancer       Date:  2002-06-20       Impact factor: 7.396

Review 9.  The role of epithelial-mesenchymal transition in cancer pathology.

Authors:  Marcello Guarino; Barbara Rubino; Gianmario Ballabio
Journal:  Pathology       Date:  2007-06       Impact factor: 5.306

Review 10.  E-cadherin mediated adhesion system in cancer cells.

Authors:  H Shiozaki; H Oka; M Inoue; S Tamura; M Monden
Journal:  Cancer       Date:  1996-04-15       Impact factor: 6.860

View more
  23 in total

Review 1.  Galectin-9: From cell biology to complex disease dynamics.

Authors:  Sebastian John; Rashmi Mishra
Journal:  J Biosci       Date:  2016-09       Impact factor: 1.826

Review 2.  Galectins in cancer: carcinogenesis, diagnosis and therapy.

Authors:  Ali Hasan Ebrahim; Zainab Alalawi; Leonardo Mirandola; Rahman Rakhshanda; Scott Dahlbeck; Diane Nguyen; Marjorie Jenkins; Fabio Grizzi; Everardo Cobos; Jose A Figueroa; Maurizio Chiriva-Internati
Journal:  Ann Transl Med       Date:  2014-09

3.  Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia.

Authors:  Qing Zhou; Meghan E Munger; Rachelle G Veenstra; Brenda J Weigel; Mitsuomi Hirashima; David H Munn; William J Murphy; Miyuki Azuma; Ana C Anderson; Vijay K Kuchroo; Bruce R Blazar
Journal:  Blood       Date:  2011-03-08       Impact factor: 22.113

4.  Galectin-9 predicts postoperative recurrence and survival of patients with clear-cell renal cell carcinoma.

Authors:  Hangcheng Fu; Yidong Liu; Le Xu; Weisi Liu; Qiang Fu; Haiou Liu; Weijuan Zhang; Jiejie Xu
Journal:  Tumour Biol       Date:  2015-02-26

5.  A possible role of galectin-9 in the pulmonary fibrosis of patients with interstitial pneumonia.

Authors:  Nobuhiro Matsumoto; Shigeki Katoh; Shigehisa Yanagi; Yasuji Arimura; Masatoshi Tokojima; Masaki Ueno; Mitsuomi Hirashima; Masamitsu Nakazato
Journal:  Lung       Date:  2013-01-16       Impact factor: 2.584

6.  The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux.

Authors:  Valerie R Wiersma; Marco de Bruyn; Yunwei Wei; Robert J van Ginkel; Mitsuomi Hirashima; Toshiro Niki; Nozomu Nishi; Jin Zhou; Simon D Pouwels; Douwe F Samplonius; Hans W Nijman; Paul Eggleton; Wijnand Helfrich; Edwin Bremer
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

7.  Galectin-1, -3 and -9 Expression and Clinical Significance in Squamous Cervical Cancer.

Authors:  Simone Punt; Victor L Thijssen; Johannes Vrolijk; Cornelis D de Kroon; Arko Gorter; Ekaterina S Jordanova
Journal:  PLoS One       Date:  2015-06-12       Impact factor: 3.240

8.  Decreased galectin-9 and increased Tim-3 expression are related to poor prognosis in gastric cancer.

Authors:  Jing Jiang; Mei-Shan Jin; Fei Kong; Donghui Cao; Hong-Xi Ma; Zhifang Jia; Yin-Ping Wang; Jian Suo; Xueyuan Cao
Journal:  PLoS One       Date:  2013-12-10       Impact factor: 3.240

9.  The glycan-binding protein galectin-9 has direct apoptotic activity toward melanoma cells.

Authors:  Valerie R Wiersma; Marco de Bruyn; Robert J van Ginkel; Emily Sigar; Mitsuomi Hirashima; Toshiro Niki; Nozomu Nishi; Douwe F Samplonius; Wijnand Helfrich; Edwin Bremer
Journal:  J Invest Dermatol       Date:  2012-05-10       Impact factor: 8.551

10.  The role of TIM-containing molecules in airway disease and their potential as therapeutic targets.

Authors:  Isabel Vega-Carrascal; Emer P Reeves; Noel G McElvaney
Journal:  J Inflamm Res       Date:  2012-08-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.